ABPI attracts new members
pharmafile | August 15, 2008 | News story | |Â Â Â
UK industry body the ABPI has swelled its ranks with the addition of three new full members, bringing its total of associated companies to 73.
The newcomers include Cheshire-based Alexion Pharmaceuticals along with the UK divisions of Merz and Basilea Pharmaceuticals. A further 13 organisations which provide services in and around the industry are also set to join as general affiliates.
The ABPI's head of membership services Jeremy Way said the Association was proud to welcome such a professional and diverse range of new members.
He added: "The membership list has increased by 16 companies for the first half of 2008. There has been particular positive growth in the general affiliate membership category, proving that the ABPI is recognised as a world class trade association and respected by the wider business community."
Alexion Pharmaceuticals has expertise in immunobiology, clinical development, and human antibody engineering, and is developing treatments in for haematologic and cardiovascular disorders, autoimmune diseases and cancer.
German company Merz is celebrating its centenary year, and is currently focused on treatments in both CNS and aesthetic medicine.
Swiss group Basilea Pharmaceuticals is focused on new antibacterial, antifungal and dermatology drugs. Its late-stage portfolio includes two drugs under regulatory review – alitretinoin and ceftobiprole – and one phase III investigational drug.
The new affiliate members include Berkshire-based management training company Vybrant, London-based healthcare policy consultancy Advocate and Present Value – a new company from West Sussex that provides global business development advice.






